Parents' Recall and Reflections on Experiences Related to HPV Vaccination for Their Children

Qualitative Health Research

Volumn 26, Issue 6, 2016, Pages 842-850

  Niccolai, Linda M ^a,b   Hansen, Caitlin E ^c   Credle, Marisol ^a   Shapiro, Eugene D ^a,c  

^a YALE UNIVERSITY   (United States)

^b YALE CANCER CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

barriers; health care; human papillomavirus; immunization; pediatrics; qualitative analysis

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ATTITUDE TO HEALTH; CHILD; FEMALE; HUMAN; MALE; MIDDLE AGED; MINORITY GROUP; PAPILLOMAVIRUS INFECTIONS; PARENT; POVERTY; PSYCHOLOGY; UNITED STATES; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; MINORITY GROUPS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PARENTS; POVERTY; UNITED STATES; VACCINATION; YOUNG ADULT;

EID: 84962855661     PISSN: 10497323     EISSN: 15527557     Source Type: Journal    
DOI: 10.1177/1049732315575712     Document Type: Article

References (47)

1. Baandrup L., Blomberg M., Dehlendorff C., Sand C., Andersen K. K., Kjaer S. K., (2013). Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sexually Transmitted Diseases, 40, 130-135.
2. Becker M. H., (1974). The health belief model and personal health behavior. Health Education Monographs, 2, 324-508.
3. Brady M. T., (2014). Pediatricians can lay out evidence to allay fears over HPV vaccine. AAP News, 35, 9.
4. Brewer N. T., Gottlieb S. L., Reiter P. L., McRee A.-L., Liddon N., Markowitz L., Smith J. S., (2011). Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. Sexually Transmitted Diseases, 38, 197-204.
5. Bronfenbrenner U., (1979). The ecology of human development. Cambridge, MA: Harvard University Press.
6. Brotherton J. M., Murray S. L., Hall M. A., Andrewartha L. K., Banks C. A., Meijer D.,.Molchanoff L., (2013). Human papillomavirus vaccine coverage among female Australian adolescents: Success of the school-based approach. Medical Journal of Australia, 199, 614-617.
7. Caskey R. N., Macario E., Johnson D. C., Hamlish T., Alexander K. A., (2013). A school-located vaccination adolescent pilot initiative in Chicago: Lessons learned. Journal of Pediatric Infectious Disease Society, 2, 198-204.
8. Cates J. R., Shafer A., Diehl S. J., Deal A. M., (2011). Evaluating a county-sponsored social marketing campaign to increase mothers' initiation of HPV vaccine for their pre-teen daughters in a primarily rural area. Social Marketing Quarterly, 17, 4-26.
9. Centers for Disease Control and Prevention. (1996). Immunization of adolescents: Recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. Morbidity and Mortality Weekly Report, 45, 1-24.
10. Centers for Disease Control and Prevention. (2010). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report, 59, 626-630.
11. Centers for Disease Control and Prevention. (2011). Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee Immunization Practices, 2011. Morbidity and Mortality Weekly Report, 60, 1705-1709.
12. Centers for Disease Control and Prevention. (2013). Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013-United States. Morbidity and Mortality Weekly Report, 62, 591-595.
13. Centers for Disease Control and Prevention. (2014a). National and state vaccination coverage among adolescents aged 13-17 years, United States, 2013. Morbidity and Mortality Weekly Report, 63, 625-633.
14. Centers for Disease Control and Prevention. (2014b). Tips and time-savers for talking with parents about HPV vaccine. Retrieved from http://www.cdc.gov/vaccines/who/teens/for-hcp-tipsheet-hpv.pdf
15. Daley M. F., Kempe A., Pyrzanowski J., Vogt T. M., Dickinson L. M., Kile D.,.Shlay J. C., (2014). School-located vaccination of adolescents with insurance billing: Cost, reimbursement, and vaccination outcomes. Journal of Adolescent Health, 54, 282-288.
16. Dorell C. G., Yankey D., Santibanez T. A., Markowitz L. E., (2011). Human papillomavirus vaccination series initiation and completion, 2008-2009. Pediatrics, 128, 830-839.
17. Fiks A. G., Grundmeier R. W., Mayne S., Song L., Feemster K., Karavite D.,.Localio A. R., (2013). Effectiveness of decision support for families, clinicians, or both on HPV vaccine receipt. Pediatrics, 131, 1114-1124.
18. Gertig D. M., Brotherton J. M., Saville A. M., (2011). Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccine Program Register, Australia. Sexual Health, 8, 171-178.
19. Gorbach P. M., Galea J., (2007). Qualitative methods. In Aral S. O., Douglas J. M., (Eds.), Behavioral interventions for prevention and control of sexually transmitted diseases (pp. 447-465). New York: Springer.
20. Guest G., MacQueen K. M., Namey E. E., (2012). Applied thematic analysis. Thousand Oaks, CA: Sage.
21. Hariri S., Unger E. R., Sternberg M., Dunne E. F., Swan D., Patel S., Markowitz L. E., (2011). Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003-2006. Journal of Infectious Diseases, 204, 566-573.
22. Hendry M., Lewis R., Clements A., Damery S., Wilkinson C., (2013). "HPV? Never heard of it!": A systematic review of girls' and parents' information needs, views, and preferences about human papillomavirus vaccine. Vaccine, 31, 5152-5167.
23. Holman D. M., Benard V., Roland K. B., Watson M., Liddon N., Stokely S., (2014). Barriers to human papillomavirus vaccination among US adolescents: A systematic review of the literature. JAMA Pediatrics, 168, 76-82. doi: 10.1001/jamapediatrics.2013.2752.
24. Jemal A., Simard E. P., Dorell C., Noone A.-M., Markowitz L. E., Kohler B.,.Edwards B. K., (2013). Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. Journal of National Cancer Institute, 105, 175-201.
25. Kempe A., Barrow J., Stokley S., Saville A., Glazner J. E., Suh C.,.Dickinson M. L., (2012). Effectiveness and cost of immunization recall at school-based health centers. Pediatrics, 129, 1-7.
26. Kester L. M., Zimet G. D., Fortenberry J. D., Kahn J. A., Shew M. I., (2013). A national study of HPV vaccination of adolescent girls: Rates, predictors, and reasons for non-vaccination. Maternal Child Health Journal, 17, 879-885.
27. Laz T. H., Rahman M., Berenson A. B., (2012). An update on human papillomavirus vaccine uptake among 11-17 year old girls in the United States: National Health Interview Survey, 2010. Vaccine, 30, 3534-3540.
28. Miles M. B., Huberman A. M., (1994). Qualitative data analysis: An expanded sourcebook (2nd ed.). Thousand Oaks, CA: Sage.
29. Moss J. L., Gilkey M. B., Reiter P. L., Brewer N. T., (2012). Trends in HPV vaccine initiation among adolescent females in North Carolina, 2008-2010. Cancer Epidemiology Biomarkers & Prevention, 21, 1913-1922.
30. Moss J. L., Reiter P. L., Dayton A., Brewer N. T., (2012). Increasing adolescent immunization by webinar: A brief provider intervention at federal qualified health centers. Vaccine, 30, 4960-4963.
31. Muñoz N., Bosch F. X., de Sanjosé W., Herrero R., Castellsague X., Shah K. V.,.Meijer C. J., (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine, 348, 518-527.
32. Newmann S. J., Garner E. O., (2005). Social inequities along the cervical cancer continuum: A structured review. Cancer Causes & Control, 16, 63-70.
33. Niccolai L. M., Hansen C. E., Credle M., Ryan S. A., Shapiro E. D., (2014). Parents' views on human papillomavirus vaccination for sexually transmissible infection prevention: A qualitative study. Sexual Health, 11, 274-279.
34. Niccolai L. M., Julian P. J., Bilinski A., Mehta N. R., Meek J. I., Zelterman D., Sosa L., (2013). Area-based poverty, racial, and ethnic disparities in cervical cancer precursor rates in Connecticut, 2008-2009. American Journal of Public Health, 103, 156-163.
35. Patton M. Q., (2002). Qualitative research and evaluation methods (3rd ed.). Thousand Oaks, CA: Sage.
36. Perkins R. B., Brogly S. B., Adams W. G., Freund K. M., (2012). Correlates of human papillomavirus vaccination rates in low-income, minority adolescents: A multicenter study. Journal of Women's Health, 21, 813-820.
37. Pitts M. J., Adams Tufts K., (2013). Implications of the Virginia human papillomavirus vaccine mandate for parental vaccine acceptance. Qualitative Health Research, 23, 605-617.
38. Public Health England. (2014). Annual HPV Vaccine coverage in England: 2012-13. Retrieved from www.gov.uk/government/uploads/system/uploads/attachment-data/file/266207/HPV-AnnualDataTable2012-13-AT-acc5.pdf
39. Rand C. M., Szilagyi P. G., Albertin C., Auinger P., (2007). Additional health care visits needed among adolescents for human papillomavirus vaccine delivery within medical homes: A national study. Pediatrics, 20, 461-466.
40. Satterwhite C. L., Torrone E., Meites E., Dunne E. F., Mahajan R., Ocfemia M. C. B.,.Weinstock H., (2013). Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2008. Sexually Transmitted Diseases, 40, 187-193.
41. Schiller J. T., Castellsague X., Garland S. M., (2012). A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine, 30S, F123-F138.
42. Stubbs B. W., Panozzo C. A., Moss J. L., Reiter P. L., Whitesell D. H., Brewer N. T., (2014). Evaluation of an intervention providing HPV vaccine in schools. American Journal of Health Behavior, 38, 92-102.
43. Syrjänen K., Hakama M., Saarikoski S., (1990). Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a non-selected Finnish female population. Sexually Transmitted Diseases, 17, 15-19.
44. Ulin P. R., Robinson E. T., Tolley E. E., (2005). Qualitative methods in public health: A field guide for applied research. San Francisco: Jossey-Bass.
45. U.S. Department of Health and Human Services National Institutes of Health. (2005). Theory at a glance: A guide for health promotion practice. Retrieved from http://www.sbccimplementationkits.org/demandrmnch//wp-content/uploads/2014/02/Theory-at-a-Glance-%E2%80%93-A-Guide-For-Health-Promotion-Practice.pdf
46. Winer R. L., Lee S. K., Hughes J. P., Adam D. E., Kiviat N. B., Koutsky L. A., (2003). Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. American Journal of Epidemiology, 157, 218-226.
47. Zimet G. D., Rosberger Z., Fisher W. A., Perez S., Stupiansky N. W., (2013). Beliefs, behaviors, and HPV vaccine: Correcting the myths and misinformation. Preventive Medicine, 57, 414-418.